Cleveland Clinic's 2020 Management of Checkpoint Inhibitor-Related Toxicity


 

Adverse Events - Immunobiology of CPIs and Autoimmunity: PD-1 Pathway and Activity Is Similar to That Displayed by Cancer Patients on Anti-PD-1 Therapy

37 views
March 24, 2020
Comments 0
Login to view comments. Click here to Login